Irwin Naturals Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Klee Irwin

Chief Executive Officer (CEO)

US$305.6k

Compensación total

Porcentaje del salario del CEO	96.7%
Permanencia del CEO	2.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Insufficient Growth At Irwin Naturals Inc. (CSE:IWIN) Hampers Share Price

Dec 13

There Are Reasons To Feel Uneasy About Irwin Naturals' (CSE:IWIN) Returns On Capital

Oct 18

Irwin Naturals (CSE:IWIN) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Dec 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Klee Irwin en comparación con los beneficios de Irwin Naturals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	US$306k	US$295k	-US$4m
Sep 30 2022	n/a	n/a	US$4m
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$6m
Dec 31 2021	US$259k	US$248k	US$9m
Sep 30 2021	n/a	n/a	US$7m
Jun 30 2021	n/a	n/a	US$11m
Mar 31 2021	n/a	n/a	US$10m
Dec 31 2020	US$75k	US$69k	US$7m

Compensación vs. Mercado: La compensación total de Klee($USD305.59K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD177.17K).

Compensación vs. Ingresos: La compensación de Klee ha aumentado mientras la empresa no es rentable.

CEO

Klee Irwin (58 yo)

2.8yrs

Permanencia

US$305,593

Compensación

Mr. Klee Irwin is Chairman and Chief Executive Officer at Irwin Naturals Inc and is its Director since August 2021. He has been Chief Executive Officer and President of Omni Nutraceuticals since March 12,...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Klee Irwin	Chairman & CEO	2.8yrs	US$305.59k	sin datos
Lyle Maxson	Director	less than a year	sin datos	sin datos
Luke Lokhorst	Director	less than a year	sin datos	sin datos

0.3yrs

Permanencia media

Junta con experiencia: La junta directiva de IWIN no se considera experimentada (0.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Irwin Naturals Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

Irwin Naturals, Inc. Announces Directors Changes

Less than half of directors are independent

Irwin Naturals, Inc. Announces Election of Sheri Orlowitz as A New Director of the Company as of May 12, 2023

High number of new and inexperienced directors

Irwin Naturals Announces CFO Board Changes

Recent updates

New major risk - Revenue and earnings growth

No independent directors

Irwin Naturals, Inc. Announces Directors Changes

Third quarter 2023 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Irwin Naturals Announces Goodwill Impairment for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings released: US$1.57 loss per share (vs US$0.032 profit in 2Q 2022)

Irwin Naturals, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2023

First quarter 2023 earnings released: US$2.27 loss per share (vs US$1.12 profit in 1Q 2022)

Less than half of directors are independent

Irwin Naturals, Inc. Announces Election of Sheri Orlowitz as A New Director of the Company as of May 12, 2023

Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Serenity Health.

Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Serenity Health.

Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million.

Insufficient Growth At Irwin Naturals Inc. (CSE:IWIN) Hampers Share Price

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$0.45 loss per share (vs US$1.22 loss in 3Q 2021)

Irwin Naturals Inc. (CNSX:IWIN) agreed to acquire Serenity Health.

High number of new and inexperienced directors

Irwin Naturals Inc. (CNSX:IWIN) signed binding, arms length agreement to acquire Assets of Tri-Cities Infusion & Wellness Clinic, PLLC.

Irwin Naturals Announces CFO Board Changes

Investor sentiment improved over the past week

There Are Reasons To Feel Uneasy About Irwin Naturals' (CSE:IWIN) Returns On Capital

Irwin Naturals Inc. (CNSX:IWIN) entered into an agreement to acquire Keta Media, LLC.

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.032 (vs US$2.83 in 2Q 2021)

Irwin Naturals Inc. (CNSX:IWIN) acquired Assets from Hobie Fuerstman DO PLC.

Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Two ketamine clinics in Georgia from Invictus Clinic, LLC.

Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Assets of New England Ketamine PLLC.

Irwin Naturals Inc. (CNSX:IWIN) entered into a definitive agreement to acquire Invictus Clinic, LLC.

Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets from Hobie Fuerstman D O PLC.

First quarter 2022 earnings released: EPS: US$1.12 (vs US$3.72 in 1Q 2021)

Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of KHC Capital Group, LLC.

Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets of New England Ketamine PLLC.

Irwin Naturals Inc. to Report Q4, 2021 Results on May 03, 2022

Full year 2021 earnings released

No independent directors

Irwin Naturals Inc. (CNSX:IWIN) entered into an acquisition agreement to acquire KHC Capital Group, LLC.

Irwin Naturals (CSE:IWIN) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

No independent directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media